A Phase 1 Study Investigating AGEN1777 as a Single-Agent and in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors
Latest Information Update: 22 Aug 2024
At a glance
- Drugs BMS-986442 (Primary) ; Programmed cell death 1 receptor antagonists
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 19 Aug 2024 Status changed from active, no longer recruiting to completed.
- 25 Jan 2023 Status changed from recruiting to active, no longer recruiting.
- 13 Jan 2023 Planned End Date changed from 1 Sep 2025 to 30 Sep 2025.